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Abstract
Background: Analytical approaches for the interpretation of anti-malarial clinical trials vary
considerably. The aim of this study was to quantify the magnitude of the differences between
efficacy estimates derived from these approaches and identify the factors underlying these
differences.
Methods: Data from studies conducted in Africa and Thailand were compiled and the risk
estimates of treatment failure, adjusted and unadjusted by genotyping, were derived by three
methods (intention to treat (ITT), modified intention to treat (mITT) and per protocol (PP)) and
then compared.
Results: 29 clinical trials (15 from Africa and 14 from Thailand) with a total of 65 treatment arms
(38 from Africa and 27 from Thailand) were included in the analysis. Of the 15,409 patients
enrolled, 2,637 (17.1%) had incomplete follow up for the unadjusted analysis and 4,489 (33.4%) for
the adjusted analysis. Estimates of treatment failure were consistently higher when derived from
the ITT or PP analyses compared to the mITT approach. In the unadjusted analyses the median
difference between the ITT and mITT estimates was greater in Thai studies (11.4% [range 2.1–
31.8]) compared to African Studies (1.8% [range 0–11.7]). In the adjusted analyses the median
difference between PP and mITT estimates was 1.7%, but ranged from 0 to 30.9%. The discrepancy
between estimates was correlated significantly with the proportion of patients with incomplete
follow-up; p < 0.0001. The proportion of studies with a major difference (> 5%) between adjusted
PP and mITT was 28% (16/57), with the risk difference greater in African (37% 14/38) compared to
Thai studies (11% 2/19). In the African studies, a major difference in the adjusted estimates was
significantly more likely in studies in high transmission sites (62% 8/13) compared to studies in
moderate transmission sites (24% 6/25); p = 0.035.
Conclusion: Estimates of anti-malarial clinical efficacy vary significantly depending on the analytical
methodology from which they are derived. In order to monitor temporal and spatial trends in anti-
malarial efficacy, standardized analytical tools need to be applied in a transparent and systematic
manner.
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In the past decade, the number of anti-malarial clinical tri-
als has increased significantly. In Africa alone, the number
of such studies published between 2001 and 2005
increased three-fold compared to the number published
in the preceding five years [1]. This increase is primarily
due to greater awareness of the emergence of multidrug
resistant strains of Plasmodium falciparum and to the intro-
duction of new treatment regimens such as artemisinin
combination therapy (ACT). In addition, study designs
have evolved to include a longer duration of follow-up
and the inclusion of genotyping to distinguish recrudes-
cence from new infection [1].
Anti-malarial clinical trials are usually conducted either to
compare two or more treatment regimens (comparative
trials) or to monitor for the emergence of anti-malarial
resistance over time and in different geographical areas.
The World Health Organization (WHO) currently recom-
mends that countries change their anti-malarial treatment
policy when the cure rate for the current recommended
therapy falls below 90% and that a new anti-malarial
treatment policy be adopted only when a therapy has an
average cure rate ≥ 95% [2]. The WHO also recommends
the use of survival analysis to generate efficacy estimates;
however, in practice researchers adopt a variety of statisti-
cal methods tailored to the rationale of the specific study
[3-5]. The derived estimates are confounded further by
variations in the PCR correction methods used to distin-
guish recrudescent infections from new infections [1,6].
These methodological differences undermine attempts to
monitor and compare cure rates between locations and
over time and significantly limit the utility of clinical trials
to guide policy [7].
In general, anti-malarial efficacy can be calculated using
three approaches: per protocol, intention-to-treat and
modified intention-to-treat. In the per protocol analysis
(PP) the evaluable population includes only those
patients who are followed throughout the protocol-
defined follow-up period and in whom a clear treatment
outcome can be determined. In this approach, patients
deviating from the protocol, such as those who do not
complete follow-up, are excluded from the analysis.
Intention-to-treat analysis (ITT) adopts a conservative
approach often advocated for comparative drug trials, in
which all patients randomized to treatment are included
in the analysis and patients with incomplete follow-up
who do not reach the primary outcome of interest are gen-
erally considered treatment failures. In the third
approach, the modified intention-to-treat analysis
(mITT), survival analysis is used and patients with incom-
plete follow-up who do not reach the primary outcome of
interest are included in the analysis as non-failures, but
censored on the last day of follow-up. WHO guidelines
and several recent consensus papers advocate modified
ITT survival analysis as the most appropriate method for
monitoring anti-malarial efficacy [3,5,7,8].
The aim of the current study was to quantify the magni-
tude of the differences between efficacy estimates derived
from survival analysis of a mITT approach with that of
simple proportions from PP and ITT approaches and to
identify factors that influence these differences. Data were
compiled from 29 comparative anti-malarial clinical trials
conducted in Africa and Thailand and the derived esti-
mates of treatment failure compared.
Methods
Data sources for analysis comparisons
Individual patient data were available from 14 compara-
tive clinical trials conducted in Thailand between 1993
and 2005 and from 15 comparative clinical trials con-
ducted in Uganda and Burkina Faso between 2003 and
2007 (Additional File 1). Data were included only for
patients enrolled with uncomplicated malaria due to P.
falciparum. Drug treatment was supervised in all patients,
with daily observation until at least day 3 followed by
weekly visits up to 28, 42, or 63 days.
Thai studies
The studies in Thailand were carried out in a camp for dis-
placed persons of the Karen ethnic minority on the west-
ern border of Thailand [9]. Transmission of malaria here
is unstable and seasonal, with peaks in May through July
and December through January [10]. The estimated ento-
mological inoculation rate (EIR) and corresponding inci-
dence of malaria is low (approximately 0.5 to 1.5 cases/
person/year), with prevalence rates of 1–4% for P. falci-
parum. Overall, P. falciparum accounts for 37% of malaria
infections, with the remainder due to P. vivax. All P. falci-
parum infections and approximately 90% of P. vivax infec-
tions are symptomatic. In Thailand, patients of all ages
were enrolled, providing that they weighed more than five
kilograms. Pregnant women and patients with severe dis-
ease were excluded.
African studies
The studies in Africa were conducted in Bobo-Dioulasso,
Burkina Faso and in several study sites in Uganda. Patients
recruited were six months of age or older with no evidence
of severe disease. Plasmodium falciparum accounts for
nearly 100% of all malaria cases in these regions. In
Burkina Faso, malaria is seasonal, with transmission peak-
ing during the rainy season from May to October. All
patients were recruited from governmental health clinics.
Studies in Uganda were conducted in areas of moderate to
high transmission intensity, with peaks during two rainy
seasons from March to May and from August to Septem-
ber. Three studies, in Kampala, Apac, and Tororo, werePage 2 of 9
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district health clinics participating in the Ugandan
Malaria Surveillance Project, household sampling, or
from other outpatient clinics.
Malaria outcome classification
The key parameters for deriving the efficacy estimates were
coded identically for all studies, as described previously
[7]. Outcomes were classified according to the 2006 WHO
guidelines as adequate clinical and parasitological
response (ACPR), early treatment failure (ETF), late clini-
cal failure (LCF), late parasitological failure (LPF), or fol-
low-up interrupted (Table 1). For 24 of the 29 (83%)
studies, parasites were genotyped to distinguish recrudes-
cent and new infections due to P. falciparum, as previously
described [1,11]. All ETFs were considered to be due to
recrudescence. Patients meeting the criteria for LCF or LPF
in whom genotyping was done but results were inconclu-
sive or unavailable were classified as unsuccessfully geno-
typed.
Table 1: Treatment outcome classification system using standardised criteria [7].
Outcome Category Outcome Code Outcome Definition Africa Thailand Total
Follow-up completed 0 ACPR 4385 4604 8989
1 ETF with death 0 1 1
2 ETF with severe malaria 5 0 5
3 ETF with danger signs 39 0 39
4 ETF with parasitological criteria 58 1 59
5 ETF with clinical criteria 9 0 9
6 ETF not otherwise specified 0 11 11
7 LCF with death 0 0 0
8 LCF with severe malaria 0 0 0
9 LCF with danger signs 4 0 4
10 LCF with fever 1033 654 1687
11 LPF 1726 665 2391
12 LPF/LCF indistinguishable 0 737 737
Follow-up interrupted 13 Adverse event requiring change in anti-malarial therapy 0 2 2
14 Treatment protocol violation 4 138 142
15 Death not due to malaria 0 3 3
16 Lost to follow-up 175 955 1130
17 Use of other anti-malarials outside of study protocol 48 6 54
18 Withdrawal of consent prohibiting further follow-up 126 1 127
19 Investigator initiated withdrawal from further follow-up 7 0 7
20 Patient who does not complete follow-up for any other reason 0 12 12
ACPR = adequate clinical and parasitological response; ETF = early treatment failure; LCF = late clinical failure; LPF = late parasitological failurePage 3 of 9
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The risks of failure unadjusted and adjusted by genotyp-
ing for each treatment arm of the individual studies were
derived and compared using three analytical methods; per
protocol (PP), intention-to-treat (ITT), and modified
intention-to-treat (mITT). Although the general principles
behind these analytical approaches are well-described, in
practice subtle differences arise in the way in which the
outcome measures may be classified. For the purpose of
the present analysis, treatment outcomes were classified as
summarized in Table 2. In the ITT analyses, the evaluable
population for both the unadjusted and adjusted calcula-
tions included all patients enrolled in the study. In the PP
analysis, the evaluable population included only patients
classified as ACPR or recurrent parasitemia with P. falci-
parum (ETF, LPF, LCF) in the unadjusted calculations and
only patients classified as ACPR, ETF or LCF/LPF due to
recrudescence in the adjusted calculations. In the mITT
analyses, the evaluable population for both the unad-
justed and adjusted calculations included all patients
enrolled in the study, with the exception that LCF/LPF
outcomes with unsuccessful genotyping outcomes were
excluded from the adjusted calculations. In the PP and ITT
analyses, the risk of failure for each treatment group was
calculated as the proportion of patient classified as failure
(the numerator) divided by the number of patients in the
evaluable population (the denominator). In the mITT
analyses, the risk of failure was calculated using the Kap-
lan-Meier product limit formula with data censored for
patients who were not classified as failures and with inter-
rupted follow-up. For the unadjusted calculations,
patients with follow-up interrupted and non-falciparum
new infections were censored on the last day of observa-
tion. For the adjusted calculations, censored patients also
included those with new P. falciparum infections. Risk of
failure estimates derived from the three analytical meth-
ods are provided in Additional File 2.
The relationship between the proportion of patients with
incomplete follow-up and the risk difference were com-
pared using two different methods for estimating the risk
of failure. Incomplete follow-up included any outcome
category (listed in Table 2), where the classification of suc-
cess/failure/censored/excluded differed between any of
the three analytical methods. In the unadjusted analyses,
incomplete follow-up was defined as any patient in whom
follow-up was interrupted and those with non-falciparum
new infections. In the adjusted analyses, incomplete fol-
low-up was defined as any patient in whom follow-up was
interrupted, those with non-falciparum new infections,
those with P. falciparum new infections, and those with
unsuccessful genotyping.
Since there were exclusive differences in the study charac-
teristics between Thailand and Africa, stratified analyses
were used to evaluate factors that may contribute to the
pairwise differences in the risk of failure between the ana-
lytical methods for both the adjusted and unadjusted cal-
culations. The following potential factors associated with
incomplete follow up were included in the analysis: the
location of the study (Africa or Thailand), the duration of
study follow-up (28, 42, or 63 days), and malaria trans-
mission intensity (classified as low (EIR < 1), moderate
(EIR 1 to 100) and high (EIR > 100)).
All analyses were performed with Stata, version 10 (Stata-
Corp, College Station, Texas). A p-value < 0.05 was con-
sidered statistically significant.
Results
In total, 29 drug studies were included in the analysis,
with 65 treatment arms that enrolled 15,409 patients. Five
(17%) trials in Thailand that included eight treatment
arms were conducted prior to the introduction of geno-
typing and thus were not included in the adjusted analy-
ses. Of the 15 studies conducted in Africa, the duration of
follow-up was 28 days in 12 (80%) studies and 42 days in
3 (20%) studies. Ten (66%) trials conducted in Africa
were conducted in areas of moderate transmission inten-
sity and the remainder were conducted in areas of high
Table 2: Analytical methods used to generate estimates of anti-malarial drug efficacy.
Outcome Category Unadjusted by genotyping Adjusted by genotyping
ITT mITT PP ITT mITT PP
Follow-up interrupted Failure Censored Excluded Failure Censored Excluded
ACPR Success Success Success Success Success Success
ETF Failure Failure Failure Failure Failure Failure
LCF and LPF Recrudescence Failure Failure Failure Failure Failure Failure
P. falciparum new infection Failure Failure Failure Success Censored Excluded
Genotyping unsuccessful Failure Failure Failure Failure Excluded Excluded
Non-falciparum new infection Success Censored Excluded Success Censored Excluded
ITT = intention-to-treat; mITT = modified intention-to-treat; PP = per protocol
ACPR = adequate clinical and parasitological response; ETF = early treatment failure; LCF = late clinical failure; LPF = late parasitological failure
Note: Although the general principles behind these analytical approaches are well-described, in practice differences arise in the way in which the 
outcome measures may be classified, depending on the rationale of the study. The Table reflects only one set of options and is not definitive for all 
antimalarial studies.Page 4 of 9
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the duration of follow-up was 28 days for one (7%) study,
42 days for five (36%) studies, and 63 days for eight
(57%) studies. All Thai studies were conducted in an area
of low intensity transmission. Clinical outcomes for each
location (Africa and Thailand) are summarized in Table 1.
Incomplete follow-up
For analyses unadjusted by genotyping, incomplete fol-
low can be divided into two categories: patients whose fol-
low-up is interrupted prior to reaching a defined endpoint
(i.e. lost to follow-up) and recurrent malaria due to non-
falciparum infections (Table 3). In total, 29% (2,237/
7,790) of Thai patients had incomplete follow-up for the
unadjusted risk estimates, of which 50% (1,120/2,237)
had follow-up terminated early due to recurrence with P.
vivax. Incomplete follow-up was significantly less frequent
in African studies (5.3% 400/7,619, p < 0.001), with only
10% (40/400) of patients with incomplete follow-up hav-
ing recurrence with a different species. For the adjusted
analyses, patients with new P. falciparum infections and
recurrent infections that could not be genotyped were also
classified as having incomplete follow-up. These out-
comes occurred in 26% (1971/7619) of African patients,
but only 7.3% (422/5813) of Thai patients; p < 0.0001.
In Thailand, studies with a longer duration (42 days or
more) had a greater proportion of patients with incom-
plete follow-up compared to studies with only 28-days of
follow-up. This was apparent for both the unadjusted
(median 22% vs 27%; p = 0.028) and adjusted analyses
(median 22% vs 35%; p = 0.004). In Africa, where there
was variation in transmission intensity, incomplete fol-
low-up in the adjusted analyses was significantly higher in
areas of high transmission (median 47% [range: 32.2–
68.6]) compared to studies in moderate transmission
areas (19% [9.9–48.2]; p < 0.001). Patients with new P.
falciparum infections accounted for 91% (1101/1204) of
the patients with incomplete follow-up in high transmis-
sion areas, compared to 65% (763/1,167) in moderate
transmission areas; p < 0.0001. Conversely, in the unad-
justed analyses, the proportion of patients with incom-
plete follow-up was low in both high transmission sites
(median 1.9% [range 0.6–6.2]) and moderate transmis-
sion sites (median 4.5% [range 2.2–12.8]).
Comparison of ITT and mITT analyses
The unadjusted risk of treatment failure derived by ITT
analysis was consistently higher than that derived by mITT
analysis (median difference = 4.7% [-0.3–31.8%]) (Table
4). The difference in risk estimates (ITT-mITT) was greater
in Thai studies (median = 11.4 [range 2.1–31.8]) com-
pared to African Studies (median 1.8% [range 0–11.7]; p
< 0.001). The difference between the unadjusted risk esti-
mates was correlated with the proportion of patients with
incomplete follow-up in African studies (rs = 0.721, p <
0.0001), although this does not reach significance in the
Thai studies (rs = 0.272, p = 0.169); Figure 1. The ITT-mITT
risk difference was higher for the adjusted estimates com-
pared to the unadjusted estimates, and this was apparent
for both the African studies (median 3.5% vs 1.8%) and
the Thai studies (median 12.3% vs. 11.4%). In Africa,
18% (7/38) of treatment arms had a difference in the
unadjusted risk estimates (ITT-mITT) greater than 5%,
compared to 85% (23/27) of the studies in Thailand; p <
0.001. The corresponding figures for the difference in the
adjusted estimates were 29% (11/38) and 95% (18/19)
respectively, p < 0.001.
Comparison of PP and mITT analyses
The unadjusted risk of treatment failure derived from the
PP analyses was consistently higher than that derived
from the mITT analyses (Table 4). The median difference
(PP-mITT) in Thailand was 1.9% (range 0–10.6) and was
correlated with both the proportion of patients with
incomplete follow-up (p = 0.02) and the duration of the
study (p = 0.03). The difference in the estimates was sig-
nificantly smaller in African studies (median = 0.1%
Table 3: Proportion of patients with incomplete follow-up.
Africa Thailand Overall
Unadjusted Analysis 7619 7790 15,409
Interrupted follow-upa 360 (4.7%) 1117 (14.3%) 1477 (9.6%)
Non-falciparum new infections 40 (0.5%) 1120 (14.4%) 1160 (7.5%)
Overall 400 (5.3%) 2237 (28.7%) 2637 (17.1%)
Adjusted Analysisb 7619 5813 13,432
Interrupted follow-upa 360 (4.7%) 673 (11.6%) 1033 (7.7%)
Non-falciparum new infections 40 (0.5%) 1023 (17.6%) 1063 (7.9%)
P. falciparum new infections 1864 (24.5%) 323 (5.6%) 2187 (16.3%)
Unsuccessful genotyping 107 (1.4%) 99 (1.7%) 206 (1.5%)
Overall 2371 (31.1%) 2118 (36.4%) 4489 (33.4%)
a Includes all patients with interrupted follow-up (outcomes 13–20 in table 1)
b Excludes 1977 Thai patients (from 5 studies with 8 treatment arms) in which genotyping was not attemptedPage 5 of 9
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study duration (p = 0.005).
In the adjusted analyses the median difference between
estimates was 1.7% (range 0–30.9) and was correlated sig-
nificantly with the proportion of patients with incomplete
follow-up (p < 0.0001; Figure 2) in both Africa and Thai-
land. The difference was greater in Africa (median 3.2%
[range 0–30.9]) compared to Thailand (median 1.0%
[range 0–6.9]; p = 0.033).
In total, 7.7% (5/65) of the treatment arms had a differ-
ence in the unadjusted risk estimates (PP-mITT) of greater
than 5%; these studies were all from Thailand (19% 5/
27), with none (0/38) conducted in Africa; p = 0.01. In the
adjusted analyses the proportion with a major difference
(> 5%), rose to 28% (16/57), with the risk greater in Afri-
can (37% 14/38) compared to Thai studies (11% 2/19).
In Africa the likelihood of a major difference in adjusted
estimates was significantly greater in studies conducted in
high transmission sites (62% 8/13) compared to moder-
ate transmission sites (24% 6/25); p = 0.035.
Discussion
Anti-malarial drug clinical trials are conducted both to
monitor anti-malarial drug resistance and to compare
treatment regimens. As in all clinical trials, protocol viola-
tions and incomplete patient follow-up challenge the
analysis and interpretation of the results. Malaria studies
are, by their nature, logistically difficult, often being con-
ducted in poorly resourced communities and prone to
Table 4: The difference in risk estimates derived by intention to treat (ITT), modified Intention to Treat (mITT), and per protocol 
(PP).
Africa Thailand Overall
ITT – mITT
Unadjusted 1.8% [-0.3–11.7]
IQR: 0.7–3.9
11.4% [2.1–31.8]a
IQR: 8.1–15.8
4.7% [-0.3–31.8]
IQR: 1.6–10.6
Adjusted 3.5% [-13.7–14.4]
IQR: 0.9–6.0
12.3% [4.1–31.8]a
IQR: 10.2–16.0
5.4% [-13.7–31.8]
IQR: 1.9–11.6
PP – mITT
Unadjusted 0.1% [0.0–2.1]
IQR: 0–0.23
1.9% [0.0–10.6]a
IQR: 0.9–4.3
0.3% [0.0–10.6]
IQR: 0.1–1.9
Adjusted 3.2% [0.0–0.9]
IQR: 0.7–3.9
1.0% [0.0–6.9]b
IQR: 0.3–1.8
1.7% [0.0–30.9]
IQR: 0.5–5.6
Values represent Median [Range], and InterQuartile Range (IQR)
Comparison between Africa and Thailand: a p < 0.001; b p = 0.033
Relationship between incomplete follow up and the risk dif-ference betwe n unadjusted es imates from ITT and mITT analysisFigur 1
Relationship between incomplete follow up and the 
risk difference between unadjusted estimates from 
ITT and mITT analysis. Closed circles for African studies 
(38 treatment arms) and open circles for Thai studies (27 
treatment arms).
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problems related to protocol adherence, anti-malarial
clinical trials are also confounded by interrupted follow-
up resulting from recurrent infections, either by the same
or different malaria species. The statistical approach to
deal with these challenges can vary according to the
rationale of the study [3,12]. For instance, in comparative
studies a conservative approach (i.e. intention to treat,
ITT), in which all patients are included in the analysis but
those with incomplete follow-up are classified as a treat-
ment failure, is often advocated. In contrast, when moni-
toring anti-malarial drug resistance, the objective is to
determine the risk of failure, with failure limited to those
with a clearly inadequate response to therapy. Patients
with incomplete follow-up can be either dropped from
the analysis (e.g. per protocol, PP), or included in a sur-
vival analysis with censoring as "non-failures" on the last
day of follow-up (modified intention to treat, mITT). The
WHO currently recommends the latter as the preferred
method of analysis of malaria drug efficacy studies [8],
although accepts the option of per protocol analysis. In
this paper, three analytical methods were compared from
drug trials conducted in Thailand, Uganda, and Burkina
Faso to determine the degree of variation in the derived
estimates of efficacy and factors underlying this.
The studies presented come from two highly experienced
research groups, and although the proportion of patients
with interrupted follow-up (i.e. incomplete follow-up due
to reasons other than recurrent infections) was generally
low, this rose to as high as 36%. Interrupted follow-up
was greater in the Thai studies compared to those con-
ducted in Africa, in part because of the longer duration of
study follow-up in Thailand. The occurrence of new P. fal-
ciparum infections or relapse of P. vivax infection, gener-
ally require retreatment and termination of the primary
study. Even in study populations with the highest adher-
ence rates, these proportions can often exceed a third of all
patients enrolled (Additional File 1), reducing considera-
bly the per protocol population. Predictably incomplete
follow-up was higher for the adjusted estimates, which
distinguishes recurrent infections, and in the African stud-
ies this was more apparent in studies conducted in areas
of high transmission.
The proportion of patients with incomplete follow-up has
significant implications for the derived estimates of treat-
ment efficacy. Both the ITT and PP methods consistently
over-estimated the risk of failure when compared to the
preferred mITT method, the discrepancy in risk estimates
varying from trivial to highly significant. For example, in
the comparison of the unadjusted ITT and mITT failure
estimates, 46% (30/65) of the difference in estimates
exceeded 5%, with one study having a difference of
31.8%. The bias was most pronounced in Thailand due to
the high percentage of patients with incomplete follow-
up. These findings highlight that although the ITT method
of analysis has utility for conservatively comparing treat-
ment arms within a comparative drug trial, it is signifi-
cantly biased when deriving point estimates of efficacy,
for comparison over time or geographical location.
New infection with P. falciparum constituted an additional
confounding factor for the adjusted analyses (PP-mITT).
Whereas individuals with such infections are removed
from the PP analysis, they are censored in the mITT anal-
ysis after contributing a period of observation to the
cumulative risk during which treatment failure was not
observed. As a consequence, the PP analysis consistently
overestimates treatment failure compared to that derived
by the mITT survival analysis (median = 1.7% [IQR 0.5–
5.6]). In 28% (16/57) of cases this difference exceeded an
absolute value of 5%. The discrepancy was particularly
apparent in the high transmission sites in Africa where
reinfections were highest. The differences in risk estimates
were lower for the unadjusted analyses, although in Thai-
land, high relapse rates with P. vivax and greater loss to
follow-up resulted in 18.5% (5/27) of PP estimates devi-
ating by more than 5% from the mITT estimate.
Survival analysis is being used increasingly to derive esti-
mates of anti-malarial treatment efficacy. Although the
ease of calculating the simple proportions in the PP anal-
ysis retains its appeal, and these estimates continue to be
reported frequently in the literature, caution is needed
when generating temporal and geographical trends using
different analytical methods. This is particularly true for
studies with poorer patient adherence to follow-up,
higher incidence of P. vivax relapse, or a high incidence of
new P. falciparum infections. Furthermore, since the pro-
portion of reinfections and relapses observed in clinical
trials is dependent upon the efficacy of the drug and its
pharmacokinetic properties, the potential bias introduced
by methodologies has implications for the comparative
analysis of antimalarials.
Given the variations in study methods, survival analysis
remains the preferred approach for monitoring in vivo effi-
cacy. First, survival analysis allows for all available data to
contribute to the analysis, thus increasing the precision of
the derived estimates. Second, it avoids systematic biases
introduced by dropping from the analysis patients who
do not complete follow-up (PP) or classifying failures as
patients who do not complete follow-up (ITT). Finally,
survival analysis allows for data from patients with differ-
ent follow-up periods to be combined to generate efficacy
estimates at different time points, thus enabling direct
comparison between studies with different lengths of fol-
low-up [7].Page 7 of 9
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availability of highly effective anti-malarial regimens
must be an integral part of any realistic approach to
achieving the global elimination of malaria [13]. Current
international guidelines advocate that new anti-malarial
treatments should be introduced only if they yield cure
rates greater than 90%. Once introduced, the efficacy of
such novel regimens needs to be monitored regularly in
order to detect early signs of declining efficacy. Even small
fluctuations in risk estimates or wide confidence intervals
can have huge implications for policy makers. In order to
monitor temporal and spatial trends in anti-malarial effi-
cacy, in vivo efficacy data need to be collated at an individ-
ual patient level and standardized analytical tools applied
in a transparent and systematic manner [7]. The recently
launched WorldWide Antimalarial Resistance Network
(WWARN – http://www.wwarn.org), aims to do precisely
that; gather global anti-malarial efficacy data and provide
open access to their uniform interpretation.
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